{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:22:41Z","timestamp":1783092161578,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04830-5","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:54:52Z","timestamp":1778324092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0592-2878","authenticated-orcid":false,"given":"Xinye","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8774-6662","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"9959","key":"4830_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(14)60220-8.","journal-title":"Lancet"},{"issue":"6","key":"4830_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J, Zhuang H. Chinese society of hepatology, chinese medical association; chinese society of infectious diseases, chinese medical association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425\u201342. https:\/\/doi.org\/10.14218\/JCTH.2023.00320.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"4830_CR3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021.","journal-title":"J Hepatol"},{"issue":"4","key":"4830_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399. https:\/\/doi.org\/10.1002\/hep.","journal-title":"Hepatology"},{"issue":"11","key":"4830_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","volume":"18","author":"Y Sun","year":"2020","unstructured":"Sun Y, Wu X, Zhou J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol. 2020;18(11):2582\u2013e25916. https:\/\/doi.org\/10.1016\/j.cgh.2020.03.001.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4830_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1186\/s12885-021-08483-3","volume":"21","author":"F Sun","year":"2021","unstructured":"Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer. 2021;21(1):1103. https:\/\/doi.org\/10.1186\/s12885-021-08483-3.","journal-title":"BMC Cancer"},{"issue":"6","key":"4830_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.14309\/ajg.0000000000002224","volume":"118","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Saraswat VA. Patients with compensated hepatitis B virus-related cirrhosis and low-level viremia: treat or not to treat? Am J Gastroenterol. 2023;118(6):970\u20131. https:\/\/doi.org\/10.14309\/ajg.0000000000002224.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4830_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039.","journal-title":"J Hepatol"},{"issue":"9","key":"4830_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021;54(9):1134\u201349. https:\/\/doi.org\/10.1111\/apt.16611.","journal-title":"Aliment Pharmacol Ther"},{"key":"4830_CR10","doi-asserted-by":"publisher","unstructured":"Liu Z, Jin Q, Zhang Y et al. 96-Week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol, in press. https:\/\/doi.org\/10.14218\/JCTH.2022.00058","DOI":"10.14218\/JCTH.2022.00058"},{"key":"4830_CR11","doi-asserted-by":"publisher","first-page":"1165990","DOI":"10.3389\/fphar.2023.1165990","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zhou J, Li Y, et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Front Pharmacol. 2023;14:1165990. https:\/\/doi.org\/10.3389\/fphar.2023.1165990.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4830_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14218\/JCTH.2024.00364","volume":"13","author":"Y Li","year":"2025","unstructured":"Li Y, Lin Y, Gou G, Cui D, Gao X, Xu G, et al. Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B: a real-world, multicenter study. J Clin Transl Hepatol. 2025;13(3):207\u201315. https:\/\/doi.org\/10.14218\/JCTH.2024.00364.","journal-title":"J Clin Transl Hepatol"},{"key":"4830_CR13","doi-asserted-by":"publisher","unstructured":"Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF et al. (2014). Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29(5):1028-34. https:\/\/doi.org\/10.1111\/jgh.12476","DOI":"10.1111\/jgh.12476"},{"issue":"2","key":"4830_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","volume":"66","author":"JH Kim","year":"2017","unstructured":"Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335\u201343. https:\/\/doi.org\/10.1002\/hep.28916.","journal-title":"Hepatology"},{"issue":"6","key":"4830_CR15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/JCTH.2021.00046","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, Ren H, Hu P. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol. 2021;9(6):850\u20139. https:\/\/doi.org\/10.14218\/JCTH.2021.00046.","journal-title":"J Clin Transl Hepatol"},{"issue":"15","key":"4830_CR16","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/QAD.0000000000002350","volume":"33","author":"A Milinkovic","year":"2019","unstructured":"Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387\u201391. https:\/\/doi.org\/10.1097\/QAD.0000000000002350.","journal-title":"AIDS"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04830-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04830-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:08:56Z","timestamp":1783091336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04830-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4830"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04830-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Approval Committee is the Ethics Committee of Beijing You \u2018an Hospital, Capital Medical University. Approval number: LL-2024-137-K. According to the requirements of the Guidelines for Ethical Review of Biomedical Research Involving Human Subjects in Healthcare Institutions in Beijing Area issued by the Beijing Municipal Health Commission, retrospective studies that meet the criteria for minimal risk may be exempted from informed consent. The ethics committee review board waived the requirement of written informed consent for participation from the participants or the participants\u2019 legal guardians\/next of kin because this is a retrospective study, and the patient data used were formed during the normal diagnosis and treatment of patients, and did not cause any additional harm to patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"404"}}